Skip to main content
. 2016 Jul 19;282(1):281–288. doi: 10.1148/radiol.2016152100

Figure 4:

Figure 4:

Bar graphs show that high LSF does not indicate the presence of extrahepatic metastases or lack of prior bevacizumab treatment. A, In patients with extrahepatic metastases (left) or specifically pulmonary metastases (right), LSF was not significantly increased. B, In patients who had previously been treated with the antiangiogenic agent bevacizumab, LSF was not significantly decreased.